Aminocaproic Acid Brand Name– Amicar
What is Aminocaproic Acid
Aminocaproic acid is an oral and parenteral inhibitor of fibrinolysis. It is indicated for enhancing hemostasis when fibrinolysis contributes to bleeding, in conditions such as aplastic anemia, abruptio placentae, hepatic cirrhosis, neoplastic disease, and in surgical complications after cardiac surgery and portavacal shunt.
Do not administer aminocaproic acid without a definite diagnosis and/or laboratory finding indicative for hyperfibrinolysis or if there is evidence of an active intravascular clotting process.
Aminocaproic acid use may theoretically result in clotting or thrombosis. However, there is no direct evidence that aminocaproic acid use has been responsible for the few reported cases of intravascular clotting after treatment.
Rather, it appears that such intravascular clotting was most likely attributable to the patient’s preexisting clinical condition, such as disseminated intravascular coagulation (DIC).
- angioedema prophylaxis
- dental bleeding
- hemorrhagic cystitis
- intracranial rebleeding prophylaxis
- subarachnoid hemorrhage
- surgical bleeding prophylaxis
For the treatment of hemorrhage caused by hyperfibrinolysis
- abdominal pain
- anaphylactoid reactions
- arrhythmia exacerbation
- ejaculation dysfunction
- increased intracranial pressure
- injection site reaction
- nasal congestion
- pulmonary embolism
- renal failure (unspecified)
- skin necrosis
- visual impairment
- creatine phosphokinase (CPK)
- disseminated intravascular coagulation (DIC)
- laboratory test interference
- Anti-inhibitor Coagulant Complex
- Factor IX
- Prothrombin Complex Concentrate, Human
- Thrombolytic Agents
- Tretinoin, ATRA